Abiopharma

🔍 Kalofonos Isabel (Executive)

Company: Crinetics Pharmaceuticals, Inc. (CRNX)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 2,500 shares of Common Stock at $40.59 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,334.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,500 shares of Common Stock at $55.0 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 834.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 2,500 shares of Stock Option (Right to Buy) at $40.59 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2035-01-10 | equity_swap_involved: 0 | shares_owned_after: 97,500.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
• F2: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025.
• F3: The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.
• F4: The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.